

## SUPPLEMENTAL MATERIAL

**Table.** Clinical characteristics of patients treated with omalizumab in association with antihistamines and without antihistamines

<b>Patients characteristics (n=162)</b>	<b>With antihistamine (n=118)</b>	<b>Without antihistamine (n=44)</b>	<b><i>p</i></b>
Female (%)	87.3	70.5	0.02
Current age (y) (mean, SD)	44.0 (15.2)	41.3 (13.4)	NS
Duration of disease before introduction of omalizumab treatment (y) (median, range)	14.0 (3-478)	19.5 (2-216)	0.03
Angioedema (%)	76.7	81.8	NS
Total serum IgE (IU/mL) (median, range)	93.2 (0.31-1734)	87.0 (4.8-1134)	NS
UAS7 scores before treatment with omalizumab	26.6	28.8	NS